SPOTLIGHT -
May 16th 2024
Industry experts gather to discuss the current investor market and how the IRA may impact the industry in the coming years.
May 15th 2024
Novo Holdings is expected to acquire 60% of Single Use Support, with the remaining shares being held by Danaher and the company founders.
May 14th 2024
The joint venture aims to address unmet needs in the treatment of mood and anxiety disorders through novel neuroplastogens.
May 13th 2024
Led by Decheng Capital, the successful round of funding also included participation from investors such as Cormorant Asset Management, Surveyor Capital, and the Foundation for Prader-Willi Research.
These factors provide investors with enough information to identify promising investment opportunities.
Novartis Terminates Licensing Rights With Allarity for Cancer Drug Due to Missed Payments
Novartis rescinds rights to to develop and commercialize multi-tyrosine kinase inhibitor dovitinib due to a material breach by Allarity for lack of financial payment.
Dexcom Announces Preliminary and Unaudited Revenue For Fourth Quarter and Fiscal Year 2023
The company also announced that it has submitted its new glucose monitoring system to the FDA for approval.
Will Calendar Change Bring an End to Run of Volatility in Biotech?
There’s reason to believe that a positive pivot may be in the offing.
Express Scripts to Launch New Network Option With Simpler Drug Pricing Structure
Express Scripts has announced plans to offer to a new pharmacy network cost-based pricing option for prescription medications and pharmacy services.
Reading the Tea Leaves for Biotech As 2024 Approaches
Could the sector please get a little ‘rate’ relief?
Obesity Drugs in the Payer Market: What to Expect
Payers won’t let these products break the bank.
Are We Close to a Peak in Interest Rates?
When you know it is coming—but it takes forever to get there.
No Rate Relief in Sight for Biotech
Strong economic data in other sectors mean rising ‘real’ rates.
More Evidence is Pointing to Potential Swing for Biotech
Could the sector be nearing a turning point in performance?
Jami Rubin Announced as Boundless Bio Chief Financial Officer
New executive brings over 30 years of experience in the biopharma industry.
Shifting Macro Trends Offer Hope for Biotech Performance Boost
But will Washington’s dealmaking stance upend the momentum?
‘Bolus’ Markets: Unique Business Opportunities with Promise and Risk
Conditions require a disciplined approach to drug pricing.
The Quest to Fully Address Prescription Drug Affordability
The Medicare Part D cap won’t solve need for financial assistance.
Could a Rates Pivot By Fed Change Biotech’s Fate?
Such a scenario is one possibility as the bear market languishes on.
When to Utilize Commercial Outsourcing
When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.
Will Recent Surge in M&A Dealmaking Save Biotech Sector?
The ‘blistering’ pace may further divide the haves from the have-nots.
Does the Biotech Sector Have Reason to Be Optimistic?
Over two years into a bear market, it still can’t catch a sustainable bid.
Biotech Challenges & Financing
Experts from Kallyope share biotech challenges they have faced and overcome as well as ways to go about securing funds in this exclusive Q&A.
Value Creation Through Portfolio-Based Corporate Strategy
Looking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.
Biopharma M&A: Year in Review, Ripples Ahead
While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.
More than Ever, Data Will Dictate Future Fortunes
Is stock market outperformance for biotech still in the cards for 2023?
An Inside Look at Pharma Revenue Management
According to the 2023 State of Revenue Report, pharma companies are prioritizing digital transformation while struggling with inflation and supply chain disruptions.
Data Signals Some Green Shoots for Biotech in 2023
Chronicling the market’s rise and fall—and signs of potential recovery.
Biopharma Investment Implications: Looking Back and Forward
What a changing economy and related trends could mean for 2023.
Back in Person, Sparks Could Fly at Upcoming J.P. Morgan Conference
Will biopharma investment heat up and signal better fortunes for 2023?
The New Reality for Industry Dealmaking May be Setting In
Focus is on cash: who’s got it, who doesn’t, and what will it mean?
Discerning Dealmaking: Caution Flag Still Raised in Biopharma M&A Race
Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.
All About the Rates: The Fallout of Fed Hikes for Biotech
As fundamentals improve, potential rate plateau could ignite growth.
Q&A With Greg Rotz, PLS Advisory Leader at PwC
Rotz discusses a report he co-authored for PwC about how life sciences companies perform on the S&P 500.
21st Annual Industry Audit: Pharma Performance Check
Our latest metrics tally across seven business-key measures uncovers some familiar players pacing the field in delivering shareholder value and getting the most from their investments.